The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic HER2-low or -ultralow breast cancer. The Food and Drug Administration (FDA) ...

Evaluate the efficacy and safety profiles of current and emerging HER2-directed therapies in NSCLC, and their potential impact on treatment paradigms. (Bazhenova) Describe the difference between ...

BARCELONA, Spain — Trastuzumab deruxtecan (TDXd) shows promise as a treatment for HER2-low and HER2-ultralow hormone receptor (HR)–positive metastatic breast cancer, according to data from the ...

The pop star — who recently released her latest album, '7' — learned she had ADHD after having her second and third kids within 14 months of each other Nick Wong After welcoming her two ...

The 'Dancing with the Stars' host recently shared on a podcast that her beloved pets were killed by coyotes in 2019 Kimberlee Speakman is a digital writer at PEOPLE. She has been working at PEOPLE ...

Maggie Smith, the two-time Academy Award-winning actor who also appeared in “Downton Abbey” and the “Harry Potter” film franchise, has died at the age of 89. A star on the big and small ...

The potential to treat GEA by targeting HER2 was confirmed in 2010 when researchers showed that adding Roche’s Herceptin to chemotherapy extended OS from 11.1 months to 13.8 months. There were ...

A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastases. Senior author ...

"As many as half of patients with HER2-positive breast cancer develop brain metastases, which often has a poorer prognosis than breast cancer that hasn't spread to the brain," says Nancy Lin ...